Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial.
Abstract
Staphylococcus aureus bloodstream infection is treated with at least 14 days of intravenous antimicrobials. We assessed the efficacy and safety of an early switch to oral therapy in patients at low risk for complications related to S. aureus bloodstream infection.
Involved units
Leibniz-HKI-Authors
Identifier
doi: 10.1016/S1473-3099(23)00756-9
PMID: 38244557